Tejnaksh Healthcare Ltd Valuation Shifts Signal Changing Price Attractiveness

Valuation Metrics Show Positive Recalibration

Tejnaksh Healthcare’s price-to-earnings (P/E) ratio currently stands at 22.46, a level that has contributed to its upgraded valuation grade from very attractive to attractive as of 25 May 2026. This P/E is considerably lower than several peers in the healthcare services sector, such as KMC Speciality Hospitals at 44.75 and Suraksha Diagnostics at 46.11, signalling a relatively more reasonable price for earnings. The price-to-book value (P/BV) ratio is also modest at 1.16, indicating that the stock is trading close to its book value, which is often viewed favourably by value investors.

Enterprise value to EBITDA (EV/EBITDA) ratio, a key indicator of operational profitability relative to enterprise value, is 10.83 for Tejnaksh Healthcare. This compares favourably against peers like KMC Speciality (21.89) and Gujarat Kidney (40.91), suggesting that the company is priced more attractively relative to its earnings before interest, tax, depreciation and amortisation. However, it is slightly higher than Asarfi Hospital’s 12.43, which holds a very attractive valuation grade.

Peer Comparison Highlights Relative Value

When benchmarked against its sector peers, Tejnaksh Healthcare’s valuation stands out as attractive but not the cheapest. For instance, Hemant Surgical, another healthcare services firm, trades at a P/E of 28.96 and EV/EBITDA of 22.82, both higher than Tejnaksh’s metrics. Conversely, some companies such as Lotus Eye Hospital and Aashka Hospitals are classified as risky or do not qualify for valuation grading due to extreme multiples, with P/E ratios exceeding 2,400 and 70 respectively.

Tejnaksh’s PEG ratio is reported as 0.00, which may indicate either a lack of meaningful earnings growth projections or data unavailability. This contrasts with peers like Suraksha Diagnostics, which has a PEG of 24.87, reflecting high growth expectations priced into the stock. The return on capital employed (ROCE) and return on equity (ROE) for Tejnaksh stand at 8.28% and 6.34% respectively, modest figures that suggest moderate efficiency in capital utilisation and shareholder returns.

Stock Price and Market Capitalisation Context

Tejnaksh Healthcare’s current share price is ₹15.34, slightly down from the previous close of ₹15.39, reflecting a day change of -0.32%. The stock has traded within a 52-week range of ₹10.65 to ₹23.31, indicating significant volatility over the past year. The company is classified as a micro-cap, which often entails higher risk and lower liquidity compared to larger peers.

Despite the valuation upgrade, the company’s Mojo Score remains low at 28.0, with a Strong Sell grade as of 25 May 2026, an improvement from the previous Sell rating. This suggests that while price metrics have become more attractive, other factors such as financial health, earnings quality, or market sentiment continue to weigh on the stock’s outlook.

Performance Analysis: Returns Versus Sensex

Examining Tejnaksh Healthcare’s stock returns relative to the Sensex reveals a mixed picture. Over the past week, the stock outperformed the benchmark with a 6.38% gain compared to the Sensex’s -0.85%. However, over the one-month period, the stock declined by 2.36%, slightly better than the Sensex’s -3.51% fall. Year-to-date, Tejnaksh Healthcare has delivered a modest 2.33% return, outperforming the Sensex’s significant -12.26% loss.

Longer-term returns paint a more challenging scenario. Over one year, the stock has fallen 30.27%, substantially underperforming the Sensex’s -8.40%. The three-year and five-year returns are deeply negative at -56.45% and -48.78% respectively, while the Sensex gained 18.98% and 45.41% over the same periods. Even over a decade, Tejnaksh Healthcare’s 118.55% return lags behind the Sensex’s 180.55%, highlighting persistent underperformance despite recent valuation improvements.

Implications for Investors

The shift in valuation grade from very attractive to attractive reflects a recalibration of market expectations and price levels for Tejnaksh Healthcare. The company’s relatively low P/E and EV/EBITDA ratios compared to peers suggest that the stock may offer value opportunities for investors seeking exposure to the healthcare services sector at a reasonable price. However, the modest returns on capital and equity, combined with the Strong Sell Mojo Grade, caution investors to consider underlying operational and financial risks.

Investors should also weigh the company’s micro-cap status, which can entail higher volatility and liquidity constraints. The mixed performance relative to the Sensex, especially over longer horizons, underscores the importance of a thorough fundamental analysis before committing capital.

Conclusion: Valuation Improvement Offers Cautious Optimism

Tejnaksh Healthcare Ltd’s recent upgrade in valuation attractiveness signals a positive shift in market perception, driven by relatively low P/E and EV/EBITDA multiples compared to sector peers. However, the company’s financial performance and stock returns have been underwhelming over medium to long-term periods, and the Strong Sell Mojo Grade reflects ongoing concerns.

For investors, the stock may represent a value proposition within the healthcare services micro-cap space, but it requires careful consideration of operational fundamentals and risk factors. Monitoring future earnings growth, capital efficiency improvements, and market sentiment will be critical to assessing whether the valuation upgrade translates into sustained share price appreciation.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →